Cargando…

A Case of Curative Treatment with Apatinib and Camrelizumab Following Liver Resection for Advanced Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC), a highly malignant digestive system tumor, poses substantial challenges due to its intricate underlying causes and pronounced post-surgery recurrence. Consequently, the prognosis for HCC remains notably unfavorable. The endorsement of sorafenib and PD-L1 inhibitors fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Julu, Liang, Rong, Lu, Cheng, Lu, Lu, Li, Shuanghang, Tang, Minchao, Huang, Xi, Huang, Shilin, Mai, Rongyun, Gao, Xing, Li, Shizhuo, Zeng, Can, Lin, Yan, Ye, Jiazhou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487462/
https://www.ncbi.nlm.nih.gov/pubmed/37686291
http://dx.doi.org/10.3390/ijms241713486
_version_ 1785103247596322816
author Huang, Julu
Liang, Rong
Lu, Cheng
Lu, Lu
Li, Shuanghang
Tang, Minchao
Huang, Xi
Huang, Shilin
Mai, Rongyun
Gao, Xing
Li, Shizhuo
Zeng, Can
Lin, Yan
Ye, Jiazhou
author_facet Huang, Julu
Liang, Rong
Lu, Cheng
Lu, Lu
Li, Shuanghang
Tang, Minchao
Huang, Xi
Huang, Shilin
Mai, Rongyun
Gao, Xing
Li, Shizhuo
Zeng, Can
Lin, Yan
Ye, Jiazhou
author_sort Huang, Julu
collection PubMed
description Hepatocellular carcinoma (HCC), a highly malignant digestive system tumor, poses substantial challenges due to its intricate underlying causes and pronounced post-surgery recurrence. Consequently, the prognosis for HCC remains notably unfavorable. The endorsement of sorafenib and PD-L1 inhibitors for HCC signifies the onset of a new era embracing immunotherapy and targeted treatment approaches for this condition. Hence, comprehending the mechanisms underpinning targeted immune combination therapy has become exceedingly vital for the prospective management of HCC patients. This article initially presents a triumphant instance of curative treatment involving the combination of TKI and PD-1 inhibitor subsequent to liver resection, targeting an advanced stage HCC as classified by the BCLC staging system. The case patient carries a decade-long history of hepatitis B, having undergone a regimen of 20 courses of treatments involving apatinib and camrelizumab. Throughout the treatment period, no occurrences of grade 3 or 4 adverse events (AE) were noted. Subsequently, the patient underwent a left hepatectomy. Following the hepatectomy, their serum AFP levels have consistently remained within normal limits, and CT imaging has indicated the absence of tumor recurrence over a span of 36 months. The patient had been reviewed on time for two years after the operation. The last time a CT was performed for this patient in our hospital was 7 May 2021, and no new tumors were found. Follow-up is still ongoing. When applying combined targeted immune transformation therapy using TKI and ICI for a patient with BCLC advanced stage HCC, apatinib treatment serves a dual purpose. It inhibits the survival and angiogenesis of tumor cells, while also enhancing the efficacy of camrelizumab in obstructing the interaction between PD-1 and PD-L1. This restoration of T cell cytotoxicity subsequently facilitates the elimination of tumor cells, leading to an enhanced anticancer effect.
format Online
Article
Text
id pubmed-10487462
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104874622023-09-09 A Case of Curative Treatment with Apatinib and Camrelizumab Following Liver Resection for Advanced Hepatocellular Carcinoma Huang, Julu Liang, Rong Lu, Cheng Lu, Lu Li, Shuanghang Tang, Minchao Huang, Xi Huang, Shilin Mai, Rongyun Gao, Xing Li, Shizhuo Zeng, Can Lin, Yan Ye, Jiazhou Int J Mol Sci Case Report Hepatocellular carcinoma (HCC), a highly malignant digestive system tumor, poses substantial challenges due to its intricate underlying causes and pronounced post-surgery recurrence. Consequently, the prognosis for HCC remains notably unfavorable. The endorsement of sorafenib and PD-L1 inhibitors for HCC signifies the onset of a new era embracing immunotherapy and targeted treatment approaches for this condition. Hence, comprehending the mechanisms underpinning targeted immune combination therapy has become exceedingly vital for the prospective management of HCC patients. This article initially presents a triumphant instance of curative treatment involving the combination of TKI and PD-1 inhibitor subsequent to liver resection, targeting an advanced stage HCC as classified by the BCLC staging system. The case patient carries a decade-long history of hepatitis B, having undergone a regimen of 20 courses of treatments involving apatinib and camrelizumab. Throughout the treatment period, no occurrences of grade 3 or 4 adverse events (AE) were noted. Subsequently, the patient underwent a left hepatectomy. Following the hepatectomy, their serum AFP levels have consistently remained within normal limits, and CT imaging has indicated the absence of tumor recurrence over a span of 36 months. The patient had been reviewed on time for two years after the operation. The last time a CT was performed for this patient in our hospital was 7 May 2021, and no new tumors were found. Follow-up is still ongoing. When applying combined targeted immune transformation therapy using TKI and ICI for a patient with BCLC advanced stage HCC, apatinib treatment serves a dual purpose. It inhibits the survival and angiogenesis of tumor cells, while also enhancing the efficacy of camrelizumab in obstructing the interaction between PD-1 and PD-L1. This restoration of T cell cytotoxicity subsequently facilitates the elimination of tumor cells, leading to an enhanced anticancer effect. MDPI 2023-08-30 /pmc/articles/PMC10487462/ /pubmed/37686291 http://dx.doi.org/10.3390/ijms241713486 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Huang, Julu
Liang, Rong
Lu, Cheng
Lu, Lu
Li, Shuanghang
Tang, Minchao
Huang, Xi
Huang, Shilin
Mai, Rongyun
Gao, Xing
Li, Shizhuo
Zeng, Can
Lin, Yan
Ye, Jiazhou
A Case of Curative Treatment with Apatinib and Camrelizumab Following Liver Resection for Advanced Hepatocellular Carcinoma
title A Case of Curative Treatment with Apatinib and Camrelizumab Following Liver Resection for Advanced Hepatocellular Carcinoma
title_full A Case of Curative Treatment with Apatinib and Camrelizumab Following Liver Resection for Advanced Hepatocellular Carcinoma
title_fullStr A Case of Curative Treatment with Apatinib and Camrelizumab Following Liver Resection for Advanced Hepatocellular Carcinoma
title_full_unstemmed A Case of Curative Treatment with Apatinib and Camrelizumab Following Liver Resection for Advanced Hepatocellular Carcinoma
title_short A Case of Curative Treatment with Apatinib and Camrelizumab Following Liver Resection for Advanced Hepatocellular Carcinoma
title_sort case of curative treatment with apatinib and camrelizumab following liver resection for advanced hepatocellular carcinoma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487462/
https://www.ncbi.nlm.nih.gov/pubmed/37686291
http://dx.doi.org/10.3390/ijms241713486
work_keys_str_mv AT huangjulu acaseofcurativetreatmentwithapatinibandcamrelizumabfollowingliverresectionforadvancedhepatocellularcarcinoma
AT liangrong acaseofcurativetreatmentwithapatinibandcamrelizumabfollowingliverresectionforadvancedhepatocellularcarcinoma
AT lucheng acaseofcurativetreatmentwithapatinibandcamrelizumabfollowingliverresectionforadvancedhepatocellularcarcinoma
AT lulu acaseofcurativetreatmentwithapatinibandcamrelizumabfollowingliverresectionforadvancedhepatocellularcarcinoma
AT lishuanghang acaseofcurativetreatmentwithapatinibandcamrelizumabfollowingliverresectionforadvancedhepatocellularcarcinoma
AT tangminchao acaseofcurativetreatmentwithapatinibandcamrelizumabfollowingliverresectionforadvancedhepatocellularcarcinoma
AT huangxi acaseofcurativetreatmentwithapatinibandcamrelizumabfollowingliverresectionforadvancedhepatocellularcarcinoma
AT huangshilin acaseofcurativetreatmentwithapatinibandcamrelizumabfollowingliverresectionforadvancedhepatocellularcarcinoma
AT mairongyun acaseofcurativetreatmentwithapatinibandcamrelizumabfollowingliverresectionforadvancedhepatocellularcarcinoma
AT gaoxing acaseofcurativetreatmentwithapatinibandcamrelizumabfollowingliverresectionforadvancedhepatocellularcarcinoma
AT lishizhuo acaseofcurativetreatmentwithapatinibandcamrelizumabfollowingliverresectionforadvancedhepatocellularcarcinoma
AT zengcan acaseofcurativetreatmentwithapatinibandcamrelizumabfollowingliverresectionforadvancedhepatocellularcarcinoma
AT linyan acaseofcurativetreatmentwithapatinibandcamrelizumabfollowingliverresectionforadvancedhepatocellularcarcinoma
AT yejiazhou acaseofcurativetreatmentwithapatinibandcamrelizumabfollowingliverresectionforadvancedhepatocellularcarcinoma
AT huangjulu caseofcurativetreatmentwithapatinibandcamrelizumabfollowingliverresectionforadvancedhepatocellularcarcinoma
AT liangrong caseofcurativetreatmentwithapatinibandcamrelizumabfollowingliverresectionforadvancedhepatocellularcarcinoma
AT lucheng caseofcurativetreatmentwithapatinibandcamrelizumabfollowingliverresectionforadvancedhepatocellularcarcinoma
AT lulu caseofcurativetreatmentwithapatinibandcamrelizumabfollowingliverresectionforadvancedhepatocellularcarcinoma
AT lishuanghang caseofcurativetreatmentwithapatinibandcamrelizumabfollowingliverresectionforadvancedhepatocellularcarcinoma
AT tangminchao caseofcurativetreatmentwithapatinibandcamrelizumabfollowingliverresectionforadvancedhepatocellularcarcinoma
AT huangxi caseofcurativetreatmentwithapatinibandcamrelizumabfollowingliverresectionforadvancedhepatocellularcarcinoma
AT huangshilin caseofcurativetreatmentwithapatinibandcamrelizumabfollowingliverresectionforadvancedhepatocellularcarcinoma
AT mairongyun caseofcurativetreatmentwithapatinibandcamrelizumabfollowingliverresectionforadvancedhepatocellularcarcinoma
AT gaoxing caseofcurativetreatmentwithapatinibandcamrelizumabfollowingliverresectionforadvancedhepatocellularcarcinoma
AT lishizhuo caseofcurativetreatmentwithapatinibandcamrelizumabfollowingliverresectionforadvancedhepatocellularcarcinoma
AT zengcan caseofcurativetreatmentwithapatinibandcamrelizumabfollowingliverresectionforadvancedhepatocellularcarcinoma
AT linyan caseofcurativetreatmentwithapatinibandcamrelizumabfollowingliverresectionforadvancedhepatocellularcarcinoma
AT yejiazhou caseofcurativetreatmentwithapatinibandcamrelizumabfollowingliverresectionforadvancedhepatocellularcarcinoma